Contemporary management of nodal and primary splenic marginal zone lymphoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Contemporary management of nodal and primary splenic marginal zone lymphoma
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 12, Issue 12, Pages 1011-1022
Publisher
Informa UK Limited
Online
2019-10-17
DOI
10.1080/17474086.2020.1681962
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
- (2019) Gilles Salles et al. Clinical Lymphoma Myeloma & Leukemia
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
- (2019) John P. Leonard et al. JOURNAL OF CLINICAL ONCOLOGY
- DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
- (2019) Ian W. Flinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
- (2019) Yunhang Guo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance
- (2018) Christina Kalpadakis et al. BLOOD
- Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
- (2018) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations
- (2018) V. Pillonel et al. LEUKEMIA
- Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience
- (2018) Bhagirathbhai R. Dholaria et al. LEUKEMIA & LYMPHOMA
- Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
- (2018) S de Vos et al. ANNALS OF ONCOLOGY
- Validation of the Marginal Zone Lymphoma International Prognostic Index
- (2018) Joohyun Hong et al. ANNALS OF HEMATOLOGY
- Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study
- (2018) Emilio Iannitto et al. BRITISH JOURNAL OF HAEMATOLOGY
- IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL)
- (2017) M. Herold et al. HEMATOLOGICAL ONCOLOGY
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
- (2017) Martin Dreyling et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402
- (2016) Michael E. Williams et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies
- (2016) Sarah J. Nagle et al. CANCER JOURNAL
- Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi
- (2016) S. Sacchi et al. HAEMATOLOGICA
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
- (2016) Laurie H Sehn et al. LANCET ONCOLOGY
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi
- (2016) S. Sacchi et al. HAEMATOLOGICA
- A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas
- (2015) Bruce D. Cheson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
- (2015) M. Parry et al. CLINICAL CANCER RESEARCH
- Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi
- (2014) L. Arcaini et al. ANNALS OF ONCOLOGY
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
- (2014) I. W. Flinn et al. BLOOD
- Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
- (2014) I. W. Flinn et al. BLOOD
- Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma
- (2014) Joseph M. Tuscano et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group
- (2014) Annarita Conconi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas
- (2014) E. Zucca et al. CLINICAL CANCER RESEARCH
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
- (2014) Nathan H Fowler et al. LANCET ONCOLOGY
- KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype
- (2014) A Clipson et al. LEUKEMIA
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation
- (2013) N Martínez et al. LEUKEMIA
- Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy
- (2013) C. Kalpadakis et al. ONCOLOGIST
- Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases
- (2012) Carlos Montalbán et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma
- (2012) Andreas Heilgeist et al. CANCER
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Marginal Zone Lymphomas With Plasmacytic Differentiation and Related Disorders
- (2011) Thierry J. Molina et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
- (2010) A. Rinaldi et al. BLOOD
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- (2009) Thomas E. Witzig et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started